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Abstract
Background: Despite steady gains in life expectancy, individuals with cystic fibrosis (CF) lung disease still experience rapid
pulmonary decline throughout their clinical course, which can ultimately end in respiratory failure. Point-of-care tools for accurate
and timely information regarding the risk of rapid decline is essential for clinical decision support.
Objective: This study aims to translate a novel algorithm for earlier, more accurate prediction of rapid lung function decline in
patients with CF into an interactive web-based application that can be integrated within electronic health record systems, via
collaborative development with clinicians.
Methods: Longitudinal clinical history, lung function measurements, and time-invariant characteristics were obtained for 30,879
patients with CF who were followed in the US Cystic Fibrosis Foundation Patient Registry (2003-2015). We iteratively developed
the application using the R Shiny framework and by conducting a qualitative study with care provider focus groups (N=17).
Results: A clinical conceptual model and 4 themes were identified through coded feedback from application users: (1) ambiguity
in rapid decline, (2) clinical utility, (3) clinical significance, and (4) specific suggested revisions. These themes were used to
revise our application to the currently released version, available online for exploration. This study has advanced the application’s
potential prognostic utility for monitoring individuals with CF lung disease. Further application development will incorporate
additional clinical characteristics requested by the users and also a more modular layout that can be useful for care provider and
family interactions.
JMIR Med Inform 2020 | vol. 8 | iss. 12 | e23530 | p. 1https://medinform.jmir.org/2020/12/e23530
(page number not for citation purposes)
Wolfe et alJMIR MEDICAL INFORMATICS
XSL•FO
RenderX
Conclusions: Our framework for creating an interactive and visual analytics platform enables generalized development of
applications to synthesize, model, and translate electronic health data, thereby enhancing clinical decision support and improving
care and health outcomes for chronic diseases and disorders. A prospective implementation study is necessary to evaluate this
tool’s effectiveness regarding increased communication, enhanced shared decision-making, and improved clinical outcomes for
patients with CF.
(JMIR Med Inform 2020;8(12):e23530) doi: 10.2196/23530
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Introduction
Background
Cystic fibrosis (CF) is a life-limiting, recessively inherited
disease resulting from mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. Irregular
functioning of the CFTR protein, which controls the transport
of water and salt across epithelial cells in different organ
systems, primarily affects the lungs [1]. Forced expiratory
volume in 1 second (FEV1), expressed as a percentage of an
individual’s predicted value based on normative standards for
age, race, height, and sex (percent predicted FEV1), is a measure
of airway obstruction and a primary indicator of CF disease
progression, severity, and efficacy of therapeutic interventions
[2]. Acute decreases in FEV1, clinically termed rapid decline,
occur throughout adolescence and adulthood. Early prediction
of FEV1 decline is critical in order to initiate preventative
interventions. Tools to predict rapid decline are crucial for
clinical decision support and timely intervention. Various
statistical models have been proposed and applied to understand
and predict CF lung function over time [3,4]. Linear
mixed-effects models with random intercepts and slopes are
commonly employed but are problematic because lung function
data are correlated within an individual over time in a potentially
more complex and nonlinear manner [5]. CF studies show that
lung function decline is nonlinear and heterogeneous; using an
exponential correlation structure can improve predictions of
lung function decline [5,6]. We recently used a nonstationary
Gaussian linear mixed-effects model [7] to predict rapid FEV1
decline using data from the US Cystic Fibrosis Foundation
Patient Registry (CFFPR) [8]. Specifically, we applied a
nonlinear model to simultaneously fit both population- and
individual-level FEV1 decline. We used integrated Brownian
motion instead of random slopes to account for longitudinal
correlation in each patient’s lung function trajectory. We
provided risk prediction of rapid decline in the form of
predictive probabilities.
Objective
This study’s objective was to translate our predictive algorithm
into an interactive web-based graphical user interface that can
be integrated with electronic health record systems and utilized
by CF care providers. Over a 3-year period, we codeveloped
the application with algorithm statisticians, programmers, and
CF care providers. We have detailed our development process,
including a multiphase study to acquire and incorporate clinician
feedback, and our technical approach. The resulting application,





This study was conducted in the Cystic Fibrosis Care Center
within the Division of Pulmonary Medicine of Cincinnati
Children’s Hospital Medical Center and was approved by the
Cincinnati Children’s Hospital Medical Center Institutional
Review Board. Individuals involved in CF clinical care were
eligible to participate; these included physicians, advanced
practice nurses, social workers, dieticians, pharmacists, and
respiratory therapists.
Procedures
Clinician feedback regarding the readability, feasibility, and
perceptions of the CFPOPD application was collected in 2
phases. In the first phase, participants were encouraged to
provide written feedback, drawings, and verbal comments. A
semistructured interview guide was tailored to assess a given
clinician’s experience in using the application. Subsequent to
the initial phase, additional feedback was gathered through
either individual, semistructured interviews, or focus groups.
Interview guides in the second phase were revised based on
previously conducted clinician focus groups and revisions to
the application. Clinician feedback was recorded and transcribed
by MT-STAT, a commercial medical transcription company,
and it was subsequently verified for accuracy and de-identified
by study staff. When discussion prompted examples of specific
patients or providers were referenced, names, places, family
relationships, and other potentially identifying data were
removed from the transcript [10].
Analysis
Initial interviews were analyzed using thematic analysis [11]
in which transcribed data were used to generate codes based on
participant feedback and were then grouped according to the
arising motifs. These resulting themes and subthemes were used
to advance application development.
Application Development
Data and Algorithm Development
The source of patient data used during CFPOPD development
and the algorithm’s development and validation has been
described in detail elsewhere [8]. Briefly, we obtained data for
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30,879 patients from the US CFFPR from 2003 to 2015 to train
and validate our algorithm. Our model exhibited excellent
predictive accuracy. Mean absolute percentage errors for the
forecasted FEV1 values in the validation sample for 6-month,
1-year, and 2-year intervals were within 5.6%, 6.9%, and 8.6%
of patients’ actual values, respectively. CFPOPD displays data
from 4847 patients from the validation sample. Data within
CFPOPD were de-identified by jittering demographic and
clinical measurements and reassigning a separate identifier for
the purpose of application development. Patients with CF
contributed data to the registry at regular clinic visits that
typically occurred at least once every 3 months and during
suspected pulmonary exacerbations. The algorithm requires the
input of a patient’s longitudinal clinical history, including FEV1,
the number of pulmonary exacerbations in the last year, the
number of clinic visits in the past year, the presence of
CF-related diabetes, the presence of chronic Pseudomonas
aeruginosa (Pa) infection, the presence of a persistent
methicillin-resistant Staphylococcus aureus (MRSA) infection,
and their utilization of public or private insurance. Furthermore,
the algorithm takes as inputs time-invariant characteristics,
including age and FEV1 at entry, year of birth categorized into
different cohorts, sex, and the number of F508del alleles.
Software Development
CFPOPD was built using R (version 3.6.1; R Core Team) [12]
and R Shiny (version 1.4.0.2; RStudio) [13], a framework for
interactive web applications and data visualization using R.
Other packages used for development included emo,
flexdashboard (version 0.5.1.1; RStudio), and plotly (version
4.9.2.1; Plotly) [14-16]. The software version control platform
git was used to manage changes to the source code and
implement modifications to CFPOPD functionality and features.
The source code was hosted on GitHub, where multiple
developers could track modifications to the source code,
document software issues, and catalog major revisions through
software releases. Each versioned release of the CFPOPD web
application was deployed within a Docker container and stored
on DockerHub to ensure a reproducible and automated
workflow. A public version of the application suitable for
interactive exploration is hosted online [9]. This paper describes
version 7.1 of the software application.
Results
Initial Application Development
The progression of our application development is depicted in
Figure 1 and shows screenshots of 4 CFPOPD versions (versions
1, 3, 5, and 7.1) in which significant revisions were
implemented. Preliminary clinician feedback from CF chart and
data conferences provided a blueprint for a bootstrap layout and
structure, which was developed during the first 3 versions of
CFPOPD [17]. The underlying layout and structure from
CFPOPD (version 3) prior to formal clinician feedback remain
the same in the current version, 7.1 (Figure 1). Clinician
participants formally reviewed versions 3 and 7.1, and a subset
of participants commented on intermittent updates to CFPOPD.
Figure 1. Progression of Cystic Fibrosis Point of Personalized Detection (CFPOPD) across multiple versioned releases. From versions 1 (top left) to
3 (top right), additional pulmonary function plots for the rate of forced expiratory volume in 1 second (FEV1) change and the risk of rapid decline was
added. In version 5 (bottom left), users were given the ability to adjust the delta threshold to calculate the risk of rapid decline, and covariate information
was moved to a table in the farthest right panel rather than a banner at the bottom of the application screen. The addition of a checkbox to visualize the
initiation of modulator use was a key feature in version 7 (bottom right).
The leftmost sidebar of the application includes filtering options
to enable a clinician to subset the data based on model covariates
and other patient-level characteristics (Figure 2). Users can
select a patient to explore via a drop-down list of identification
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numbers. Patient data can also be filtered by toggling a sidebar
checkbox and slider features for patient age at entry (coded as
the first record available in the CFFPR registry data), FEV1 at
entry into the registry, patient sex, birth cohort group, F508del
copies, chronic Pa, and persistent MRSA. The list of patient
identification numbers is conditional on which features are
selected and the available data. For example, if the user alters
the minimum value for age at entry to 16 years of age, only
patients 16 years of age or older will be available for selection.
Similarly, a text box above the drop-down list displays changes
dynamically and displays the number of patients available based
on the selected filters.
Figure 2. Leftmost panel of Cystic Fibrosis Point of Personalized Detection (CFPOPD). The drop-down menu shows patient 341 has been selected.
Users can subset the patient sample by toggling options for sex, birth cohort, genotype (F508del copies), Pseudomonas aeruginosa (Pa) and Staphylococcus
aureus (MRSA) infections, and forced expiratory volume in 1 second (FEV1) and age at entry into the US Cystic Fibrosis Foundation Patient Registry.
A slider rule allows a user to select a delta threshold that is clinically relevant to a specific patient. Checkboxes allow users to select what data is viewable
in the pulmonary function plots [ie, population norms, fitted and forecasted values, pulmonary exacerbations (PEs), and modulator use]. In the pictured
instance, all subset and data viewing options have been selected.
CFPOPD has 2 main plot windows. The middle panel of our
current application (Figure 3) displays pulmonary function data
recorded over a patient’s years of clinical follow-up via 3 faceted
plots: observed percent predicted FEV1 (top), predicted rate of
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FEV1 decline (middle), and predicted risk of rapid decline
(bottom). Together, these 3 plots facilitate clinical interpretation
of a patient’s historical and future lung function trajectory.
Bands surrounding each FEV1 trajectory line show 95%
confidence intervals to demonstrate the degree of uncertainty.
Bands for fitted values are colored gray, and bands representing
2-year forecasted values are beige. For the 2-year forecasted
period, we show the predictions holding this interval of data
out of the model (the red trend line shown in each plot); the
gray trend lines represent the predictions with the data included
in the model. Both sets of trend lines were presented to clinician
focus group participants in order to show model fit and
transparency. In addition to filtering options, users can choose
what underlying data is viewable in pulmonary function plots.
In version 3, one toggle was made available that allowed users
to view population norms for the FEV1 rate of change and
observed values. Normative data is generated through dynamic
medians, which are computed based on the available patient
data as specified by the filtering options; this was a suggestion
from the aforementioned work soliciting informal feedback at
chart review and data conference sessions [17].
Figure 3. Middle panel of Cystic Fibrosis Point of Personalized Detection (CFPOPD). The 3 plots show pulmonary function data from patient 341.
The top plot displays the patient’s % predicted forced expiratory volume in 1 second (FEV1) values (circles) recorded during pulmonary function testing,
as well as the patient’s fitted (gray line) and forecasted (red line) values. Pulmonary function values recorded at the time a patient experienced a pulmonary
exacerbation are colored red. A dotted line shows normative data (dynamic medians) respective to the patients % predicted values and rate of change
in FEV1 (middle plot). The plot shows that the patient’s rate of change in FEV1 fluctuated initially but has remained stable from ages 24 to 32 years.
Compared to the overall norms, patient 341’s rate of change is analogous to other patients. Similarly, the patient’s risk of rapid decline initially fluctuated
but declined and stabilized (bottom plot). All plots show that patient 341 was prescribed a modulator at 31 years of age (blue line; ivacaftor) and a
second modulator at 32 years of age (green line; lumacaftor/ivacaftor).
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The rightmost window in version 7.1 of CFPOPD (Figure 4)
presents patient longitudinal covariate data and other disease
status information such as the number of pulmonary
exacerbations (denoted as “PEs” on the app) in the previous
year, persistent MRSA, and CF-related diabetes. In version 3
of CFPOPD, this data was displayed using points plotted over
time and colored to correspond to continuous and dichotomous
variables, including the presence (red) or absence (gray) of
clinical characteristics. Lastly, CFPOPD also displays
time-invariant covariate information such as the selected
patient’s starting age, birth cohort, sex, and number of F508del
copies. In version 3, these were shown in a horizontal table
below the plotting windows.
Figure 4. Rightmost panel of Cystic Fibrosis Point of Personalized Detection (CFPOPD). The covariate table (bottom) shows that patient 341 is female,
born between 1981 and 1988, enrolled in the Cystic Fibrosis Foundation Patient Registry at age 20, had a baseline of 84% predicted forced expiratory
volume in 1 second (FEV1), and is homozygous for F508del copies. The top bar plot shows that she has had few pulmonary exacerbations (PEs) but
numerous clinic visits throughout her clinical history. Binary covariate plots (middle) indicate that she has been diagnosed with cystic fibrosis (CF)-related
diabetes and had not developed Staphylococcus aureus (MRSA) infection but has experienced chronic Pseudomonas aeruginosa (Pa) infection since
age 20. The plots for insurance type indicate that she utilized public insurance at entry and transitioned between public and private insurance, beginning
at around 25 years of age.
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CFPOPD also features an ‘About’ tab in the top banner that
describes the purpose of the application, defines
application-specific terms, and instructs users how to use the
data filtering and data viewing options. This section also
provides a narrative of the clinical history and covariate
information for an example patient (186) to illustrate CFPOPD’s
utility in clinical practice.
A key feature of CFPOPD is the interactivity of pulmonary
function and covariate plots. Users have the capability to zoom
in and pan across a specific year in a patient’s clinical history.
Faceted FEV1 plots are also linked. For example, if a user zooms
to a specific range of ages in the bottom pulmonary function
plot where a patient’s risk of rapid decline appears to change,
the same period of interest will be displayed in the plots for
FEV1 derivative and observed FEV1 values. The scales on the
x- and y-axes also change dynamically. An additional interactive
feature includes text hovering. When a user scans across the
plots with the cursor, a text window will display the values of
the underlying data.
Focus Group and Conceptual Model
A total of 17 clinicians (6 attending pulmonologists, 1 nurse
practitioner, and 10 pulmonary research fellows) participated
in 2 formal focus group sessions (Table 1). The first session
included attending physicians and a nurse practitioner, while
the second session included fellows. Fellows were grouped
separately from attending physicians and other standing
members of the care teams, given their roles as trainees. Select
participants from the attending and nurse practitioner session
were followed up in individual interviews for additional
feedback after CFPOPD updates were made based on the focus
group. We followed up with a subset of 3 participants from the
fellows’ session. Participants were chosen for follow-up based
on the salience of their feedback. Prior iterations garnering
feedback through CF-specific chart and data conferences
consisted of 35 members across the clinical care teams.
Table 1. Focus group participant (clinician) characteristics (n=17).
Total (n=17), n (%)Men (n=8), n (%)Women (n=9), n (%)Clinician characteristics
Ethnicity
2 (12%)2 (25%)0 (0%)Hispanic or Latino
15 (88%)6 (75%)9 (100%)Not Hispanic or Latino
Race
1 (6%)0 (0%)1 (11%)Asian
2 (12%)1 (12%)1 (11%)Black/African American
14 (82%)7 (88%)7 (78%)White
As a result of focus group sessions, we developed a conceptual
model of clinician perceptions toward rapid decline and
CFPOPD integration (Figure 5). Key a priori discussion points
were the definition of rapid decline, challenges to CFPOPD
utility, and revisions (yellow boxes). The first discussion point
illuminated how clinicians use different communication
techniques with families as opposed to care teams when referring
to the rate of decline. Clinicians expressed hesitation with using
the phrase “rapid decline.” There was also difficulty expressed
in the concept of “rate of decline” and how to conceptualize
rate as velocity. Challenges to CFPOPD utility, which prompted
ways to improve the application, focused on electronic health
record (EHR) accessibility, distinguishing change in FEV1 from
artifacts, and the desire to have a decision support tool that could
help reveal patterns in FEV1 trajectories. Actionable revisions
included the development of dynamic medians, which allowed
for the use of normative data and customizable graphics.
Participants described how CFPOPD could be used to strengthen
conversations with patients and families, particularly in
promoting adherence to therapies. Another identified area of
potential clinical significance was its use in communicating
rapid disease progression during inpatient settings, as CFPOPD
could serve as a motivation to improve the clinical course or
initiate antibiotic therapy to raise lung function levels. Targeted
interviews prompted further CFPOPD developments.
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Figure 5. Conceptual clinical model of rapid decline. Larger yellow-shaded boxes with bold text represent key discussion points during focus group
sessions. The first half of the diagram summarizes clinician understanding and discussion with other care team members and patients/families. Clinicians
translated concepts of rapid decline into optimizing Cystic Fibrosis Point of Personalized Detection (CFPOPD) data visualization/monitoring capabilities.
The second half represents CFPOPD integration and clinical utility. Clinicians identified challenges to the user interface and suggested revisions. The
rightmost boxes represent clinician feedback on how the use of CFPOPD would change the conversations with families or otherwise be helpful.
Based on coded feedback from focus group participants and
semistructured interviews, 4 primary themes were identified,
providing granularity to the conceptual model in Figure 5. Each
theme and corresponding illustrative quotes from focus group
participants are shown in Textbox 1. Clinicians expressed
uncertainty regarding the definition of rapid lung function
decline (list 1, Ambiguity). The other 3 themes focused on the
CFPOPD application’s utility, clinical significance, and
suggested revisions (lists 2-4). CFPOPD facilitated the
clinicians’ ability to decipher trends in a patient’s FEV1,
recognize when a patient may be at risk of rapid FEV1 decline,
and assist in determining the clinical impact of treatment
interventions. Focus group participants stated that CFPOPD
may be a useful educational tool (list 2, quotes a-d). Visualizing
a patient’s clinical history assisted clinical adjudication (list 2,
quotes e-f). Still, some care providers expressed concern that
the CFPOPD may cause confusion in patient and family
interactions (list 2, quotes g-h). Clinician feedback demonstrated
that our application had the potential to advance clinical practice
by facilitating decision-making, discussions with patients, and
identification of rapid decline. Care providers articulated that
incorporating CFPOPD into previsit planning meetings would
improve point-of-care decision-making and facilitate
conversations between families and the care team (list 3, quote
a). Physicians stated that visualizing a patient’s risk of rapid
decline may also be used as a motivator by eliciting treatment
adherence (list 3, quote b). Clinicians recognized the value of
CFPOPD and the capability to advance clinical practice (list 3,
quotes c-f). Caution was expressed regarding its impact during
inpatient visits, as it could serve as a demotivator (list 3, quote
g). Provider feedback regarding revisions to CFPOPD has been
critical to ensuring our instrument is translational, relevant, and
impactful in clinical practice (list 4, quotes a-d).
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Textbox 1. Emergent themes and accompanying quotes from clinician focus groups.
Defining Rapid Decline:
• 1. Ambiguity
a. “[I am] more likely to refer to the curve in a clinical setting than to a threshold that is going to capture almost every patient.”
b. “Really hard to define.”
c. “If we were able to tweak [the definition] ‘rapid decline’…go for minimal change in lung function over time as opposed to something that
might be more realistic for the patient.”
Cystic Fibrosis Point of Personalized Detection (CFPOPD) Application:
• 2. Utility
a. “Oh my gosh, it’s just what I wanted.”
b. “Yes, [I] would use graphs in preclinic meetings.”
c. “… helpful both on a sort of clinical decision-making side and describing it to families’ side.”
d. “As a fellow trainee, I feel sometimes that it’s really difficult for me to see that big picture.”
e. “Great that hovering gives you the exact numbers.”
f. “If you can show some improvement in the derivative, in the trajectory, it's more cause for optimism.”
g. “I don’t think it would be helpful at all to show a family. I think it is complicated for families; it’s complicated for me.”
h. “I like graphs in talking with families, but as a clinician, I think the only one I would feel comfortable using would be the top one.”
• 3. Clinical Significance
a. “If you have a visual representation like that, it would be substantially more helpful than me verbally saying, ‘You’re getting worse faster
than we think you should.’”
b. “I would definitely show a 16-year-old who is noncompliant…‘if you don’t step it up, this is where you are going.’”
c. “10 years ago, we were just trying to look at random pieces of paper, and we never could see any of this whatsoever.”
d. “… put this in Epic.”
e. “These are things you can intervene on if you knew 5 years ago this trend was coming.”
f. “If you look at any clinical trial or any aspect of medicine, the more frequent your intervention is, the more frequent your clinic visits, the
more frequent you’re ahead of this data, the better your outcomes.”
g. “… billboard of death.”
• 4. Revisions
a. “Customize threshold for rapid decline…if you want to call rapid as 3% or as 6% or 10%...you can play with that.”
b. “Add mutation classes and modulator therapy use.”
c. “Categorize continuous covariates based on clinical severity.”
d. “Different dots and colors…what’s bad and what’s steady.”
Further Application Development
Our collaborative approach to developing CFPOPD has allowed
our team of programmers to prospectively track its evolution,
as shown in Figure 1. Data filters, pulmonary function
data-viewing options, covariate information, coloring according
to values, and icon typography were added to the application
based on feedback received from clinical application users.
Subsequent to clinician feedback, we implemented a feature to
enable users to adjust the threshold value for percent predicted
FEV1 loss or delta threshold, used to calculate a patient’s risk
of rapid decline (Textbox 1, list 4, a). This threshold can be
modified by manipulating the slider to the desired value, which
ranges from -10% to 0.5% (Figure 2). The default threshold of
-1.5% predicted/year was chosen previously [17].
We incorporated CF registry data on modulator use and mutation
type (Textbox 1, list 4, b) through a checkbox in the left sidebar
(‘Show Modulator Use?’). If a patient has been prescribed a
modulator, vertical lines are shown on each pulmonary function
graph at the age medication was first administered (Figure 3).
When hovering over the vertical line, a window stating the name
of the medication and age at administration is displayed. The
names of each patient’s CFTR gene mutations were added to
the covariate table (Figure 4).
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Clinician feedback (Textbox 1, list 4, c-d) to categorize covariate
information and assign clinical severity based on color was
applied to pulmonary exacerbation and visit frequency plots.
Pulmonary exacerbations are acute respiratory events that can
emerge from precipitous drops in lung function. We revised the
color scheme according to a categorical designation versus the
continuous scale from version 3. Occurrences greater than 5 are
colored red to designate an exceedance of the clinical threshold
(Figure 4). In order to enhance a clinician’s ability to visualize
pulmonary exacerbations and rapid decline, a checkbox option
(‘Highlight PEs?’) was added to the left sidebar (Figure 2).
When checked, a patient’s FEV1 value in the top pulmonary
function plot will be colored red if a pulmonary exacerbation
was observed (Figure 3).
Other CFPOPD revisions were based on informal feedback or
implemented to optimize application functionality and
comprehension. To maximize the space to visualize pulmonary
function plots, we repositioned the covariate table underneath
the covariate dot plot (Figure 4). We also increased the pixel
width of the pulmonary function plots to improve readability
and a checkbox that allowed users to toggle whether patient
FEV1 values are displayed in the top pulmonary function plot
(‘Show Fitted and Measured Forecasts?’). Depending on the
number of spirometry results, removing FEV1 values from the
plot may facilitate a clinician’s ability to decipher rapid decline
(Figure 3). These revisions were completed under CFPOPD
version 4.
We supplemented the covariate table with emojis to increase
the ease of visual interpretation, implemented in version 5.
Where applicable, emojis change dynamically according to the
age and sex of the selected patient. The standard symbol for
either male (♂ ) or female (♀ ) is shown to communicate the
selected patient’s sex, and depending on if the patient is younger
or older than 18 years of age, either a girl, boy, woman, or man
emoji is shown to communicate the starting age.
Lastly, binary dot plots of the number of PEs and clinic visits
a patient experienced in the previous year were modified to bar
plots in version 6. In addition to colored bars indicating clinical
severity, this second dimension enhances a user’s ability to
visually evaluate a patient’s clinical trajectory.
Discussion
Principal Findings
We developed and coproduced an interactive web application
designed to facilitate clinical point-of-care decision-making by
predicting acute pulmonary function decline in patients with
CF. We conducted focus groups with clinicians and CF care
providers to garner feedback on a prototype application [17]
and used this feedback to further develop the application in
order to advance its utility for clinical care.
Clinicians suggested insightful and actionable CFPOPD
revisions, which we incorporated over the course of 4 versioned
releases. A principal revision was to add a feature enabling care
providers to tailor the delta threshold according to their clinical
judgment and characteristics of an individual patient.
Implementing this capability was paramount to ensure CFPOPD
was applicable in clinical practice. Adding this feature also
manifested in a related theme regarding uncertainty toward a
single clinical definition of “rapid decline.”
With the advent of modulator therapies, another requested
modification was to include visualization of modulator use and
descriptive text to communicate patient mutations. While
numerous therapies exist to mitigate and treat acute symptoms
in CF, modulator therapies act at a molecular level to restore
function to CFTR protein [1,18]. By enabling care providers to
detect when a patient is at risk for acute decline in pulmonary
function, CFPOPD may facilitate clinical judgment and
decision-making regarding the initiation of acute therapies, such
as intravenous antibiotics. Previous research has shown that a
treatment of acute drops in FEV1 using intravenous antibiotics
improved long-term pulmonary function [19]. Similarly, if a
patient is currently prescribed a modulator, our application
allows care providers to track a patient’s lung function
prospectively and assess the effectiveness of personalized
treatment regimens. CFPOPD has implications for emerging
studies involving patient withdrawal of maintenance therapies,
given observed effectiveness for select combinations of
mutations and modulators.
Technological advances in electronic data storage have
transformed the management of medical records, greatly
increasing the volume of data accessible to researchers,
clinicians, and patients [20]. This abundance of information has
yielded opportunities for novel development of interactive
applications to synthesize, model, and translate EHR data [21].
Web-based applications have been employed across research
and medical domains, ranging from infection management [22]
to personalized mental health monitoring [23]. Likewise, others
have leveraged visual analytics to translate results from complex
statistical techniques used in EHR research, such as
case-crossover design [24] and hierarchical clustering [25], into
a comprehensible form. We sought to develop CFPOPD in order
to improve point-of-care decision-making, and feedback from
clinicians at our institution demonstrates our application has
the potential to do so. Furthermore, clinician responses also
indicate CFPOPD may promote communication and shared
decision-making. Previous research indicates that participatory
decision-making between physicians and their patients results
in greater patient satisfaction [26]. Care providers noted that
CFPOPD use may encourage adherence among patients with
CF that are noncompliant, and there is empirical evidence to
support this. Heisler et al [27] have shown that effective
communication and shared decision-making are associated with
positive diabetes self-management.
Limitations
Although our results indicate that CFPOPD has the potential to
positively impact clinical care, some feedback suggests that
care provider comprehension is not universal. Additional
training may be necessary before our application is fully
deployed for clinical practice. Some discord existed among
physicians as to whether our application would facilitate
conversations between patients/families and the clinical care
team, as clinicians expressed differing opinions regarding
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approaches to communicate a high risk of rapid decline. To
accommodate this limitation, future revisions to CFPOPD could
include additional options that allow care providers to customize
CPOPD’s layout by selecting only plots that are relevant to the
patient-provider discourse. Currently, CFPOPD is limited to
existing fields available from the CFFPR data. Risk calculations
are not computed in real time; rather, values are pulled from
precomputed lookup tables. While our application demonstrates
the predictive accuracy of our algorithm, further development
is needed to integrate CFPOPD into near real-time clinical
practice. Lastly, our findings are based on a single-center study
(Table 1). We anticipate drawing a larger, more diverse sample
of care teams in future multicenter studies assessing CFPOPD
feasibility and acceptability.
Future Work
Our future work will address CFPOPD limitations; chiefly, we
will strive to implement CFOPD into an EHR system to provide
“now-casting,” or near real-time statistical predictions of rapid
decline. In addition to rapid decline, a similar area of extension
is to calculate risk probabilities for pulmonary exacerbation
onset. Recently, a data-driven definition for pulmonary
exacerbation has been proposed and is being tested by the Cystic
Fibrosis Learning Network [28]. Making CFPOPD available
for use in clinical practice will enable assessment of its impact
on clinical practice and patient outcomes. It may be desirable
for patients to access their longitudinal data as well, which could
potentially be made available to patients through the medical
institution’s patient portal. Given emerging public health issues
and a drastic increase in telehealth, integrating home spirometry
into CFPOPD may become a critical priority. Combined with
access to the CFPOPD application through a care provider’s
patient portal, this extension could facilitate home monitoring
and diagnosis of acute drops in lung function among patients
with CF being clinically followed via telemedicine. The
developmental framework outlined herein is capable of
adaptation to different clinical markers or chronic diseases, such
as diabetes and asthma, for which longitudinal tracking is
valuable.
Conclusions
We developed CFPOPD to translate a novel predictive algorithm
into an interactive clinical tool to enhance early detection and
forecasting of rapid pulmonary function decline in patients with
CF. Our application was built through an iterative and
collaborative process among programmers, statisticians, and
clinicians. We have demonstrated that this framework of
collaborative design between developers and end-users is
successful, capable of delivering an impactful product, and may
be generalized to other chronic diseases and disorders that rely
on routinely collected clinical data for medical monitoring and
decision-making.
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CFFPR: Cystic Fibrosis Foundation Patient Registry
CFPOPD: Cystic Fibrosis Point of Personalized Detection
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CFTR: cystic fibrosis transmembrane conductance regulator
EHR: electronic health record
FEV1: forced expiratory volume in 1 second
MRSA: methicillin-resistant Staphylococcus aureus
Pa: Pseudomonas aeruginosa
PEs: pulmonary exacerbations
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